Klow blend reconstitution protocol

This protocol describes the reconstitution and storage of the lyophilized Klow blend in standard research workflows. Klow is the Glow formulation plus KPV — a four-compound combination spanning regenerative and anti-inflammatory research pathways. Values below reflect published handling literature for each component; study design is the responsibility of the qualified investigator.

At a glance

Parameter	Value
Recommended diluent	Bacteriostatic Water (USP, 0.9% benzyl alcohol)
Recommended volume (70 mg combined: 50 mg GHK-Cu + 5 mg BPC-157 + 5 mg TB-500 + 10 mg KPV)	3.0 mL
Final concentration	GHK-Cu: 16.7 mg/mL · BPC-157: 1.7 mg/mL · TB-500: 1.7 mg/mL · KPV: 3.3 mg/mL
Stability — lyophilized	≥24 months at -20 °C, sealed, light-protected
Stability — reconstituted	30 days at 2–8 °C, light-protected (GHK-Cu color sensitivity)
Solution appearance	Clear with distinctive deep blue tint from GHK-Cu coordination

Procedure

1. Equilibrate the vial to room temperature.
2. Sterile prep: wipe stopper with isopropyl. Use sterile syringe and needle.
3. Inject diluent slowly along the inner wall.
4. Swirl gently. Do not shake — agitation can promote oxidation of GHK-Cu's copper coordination.
5. Verify: solution should be clear with a characteristic blue color from GHK-Cu. Faded blue indicates copper dissociation; do not use.

Why these four compounds are blended

Klow adds the anti-inflammatory tripeptide KPV to the Glow regenerative blend. The combination targets four pathways with limited mechanistic overlap:

• GHK-Cu — extracellular matrix remodeling, collagen synthesis, anti-inflammatory gene expression (NF-κB modulation)
• BPC-157 — angiogenesis, fibroblast migration, vascular support
• TB-500 (Thymosin Beta-4) — cell migration into repair sites, anti-fibrotic activity
• KPV — direct anti-inflammatory effect through melanocortin-receptor-independent pathways; well-characterized in gut and dermal inflammation models

The intent behind adding KPV to the Glow base is to strengthen the inflammation-control component of the formulation — particularly relevant for research models where chronic or acute inflammation is the rate-limiting factor for tissue repair. KPV's small size (3 amino acids) also gives it favorable tissue penetration compared to the larger compounds in the blend.

Compound notes

Same handling considerations as Glow apply, with one addition:

• Preserve the copper signature — blue color indicates GHK-Cu is intact.
• Avoid metals and chelators in any dilution buffer (EDTA, strong reducing agents will strip copper).
• KPV is the most tolerant component — short sequence, robust in standard buffers, no special handling. Its presence doesn't impose any new constraints beyond what Glow already requires.

The dose-balance question is the most important design choice for research using Klow: KPV is dosed lower per administration in Klow (3.3 mg/mL) than in standalone KPV vials (5 mg/mL). Research models that need higher KPV exposure should plan accordingly — by adjusting volume per dose, or by supplementing with a standalone KPV vial.

Storage

Reconstituted blend is stable for approximately 30 days at 2–8 °C, light-protected. For longer storage, aliquot into sterile single-use tubes and freeze at -20 °C or colder. Lyophilized stability is ≥24 months at -20 °C light-protected.

Notes

This protocol describes reconstitution parameters from published handling literature for each component. It is not a recommendation for any specific research protocol or design. For research use only. Not for human or veterinary use.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Compound in the Light of the New Gene Data. Int J Mol Sci 2018;19:1987. PMID: 29986520
2. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol 2011;110:774–780. PMID: 21030672
3. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:324–331. PMID: 18092347